Description and Brand Names
Drug information provided by: IBM Micromedex
Descriptions
Tucatinib is used in combination with trastuzumab and capecitabine to treat metastatic HER2-postive breast cancer (cancer that has already spread including the brain) or whose cancer cannot be removed by surgery in patients who have received one or more anti-HER2 breast cancer treatments. It belongs to the group of medicines, called antineoplastics.
Tucatinib interferes with the growth of cancer cells, which are eventually destroyed. Since the growth of normal cells may also be affected by the medicine, other unwanted effects will also occur. Some of these may be serious and must be reported to your doctor.
This medicine is available only with your doctor's prescription.
This product is available in the following dosage forms:
Portions of this document last updated: June 01, 2022
Copyright © 2022 IBM Watson Health. All rights reserved. Information is for End User's use only and may not be sold, redistributed or otherwise used for commercial purposes.